MAZ and prostate adenocarcinoma: The deregulated expression of MYC-associated zinc finger protein (MAZ) is correlated with the progression of tumors such as colorectal adenocarcinoma [33], hepatocellular carcinoma [34], renal cell carcinoma [35], glioblastoma [36], breast carcinoma [37], and prostate adenocarcinoma [38].